文献速递妇科肿瘤

仑伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
PubMed 文献 · J Clin Oncol · 2020-03-13

本报告为正在进行的Ib/II期研究中的晚期子宫内膜癌患者队列最终主要疗效分析,患者接受仑伐替尼20 mg每日一次口服联合帕博利珠单抗200 mg每3周静脉注射。108例经治患者的中位随访为18.7个月,24周客观缓解率(ORR)为38.0%(95%CI 28.8%–47.8%),中位缓解持续时间(DOR)为21.2个月,中位无进展生存期(PFS)为7.4个月,中位总生存期(OS)为16.7个月。结论认为该联合方案在经治晚期子宫内膜癌中显示出有前景的抗肿瘤活性,且毒性可控。

要点

  • 经治晚期子宫内膜癌患者24周ORR为38.0%(95%CI 28.8%–47.8%)。
  • MSI-high患者24周ORR为63.6%(95%CI 30.8%–89.1%),MSS患者为36.2%(95%CI 26.5%–46.7%)。
  • 总体中位DOR为21.2个月,中位PFS为7.4个月,中位OS为16.7个月。

核心结论

  • 仑伐替尼联合帕博利珠单抗在经治晚期子宫内膜癌患者中显示出有前景的抗肿瘤活性,无论肿瘤MSI状态如何。
  • 该联合治疗的毒性特征可控。

研究设计与样本

  • 正在进行的Ib/II期研究中选择性实体瘤患者队列的最终主要疗效分析。
  • 患者接受仑伐替尼20 mg每日一次口服联合帕博利珠单抗200 mg每3周静脉注射,3周为一周期。
  • 主要终点为24周客观缓解率(ORRWk24);次要终点包括DOR、PFS和OS。
  • 肿瘤评估由研究者按免疫相关RECIST进行。
  • 数据截止时共纳入108例经治子宫内膜癌患者,中位随访18.7个月。

主要发现

  • 24周ORR为38.0%(95%CI 28.8%–47.8%)。
  • MSI-high亚组(n=11)24周ORR为63.6%(95%CI 30.8%–89.1%)。
  • 微卫星稳定亚组(n=94)24周ORR为36.2%(95%CI 26.5%–46.7%)。
  • 经治患者中位DOR为21.2个月(95%CI 7.6个月–不可估计),中位PFS为7.4个月(95%CI 5.3–8.7个月),中位OS为16.7个月(15.0个月–不可估计)。
  • 3级或4级治疗相关不良事件发生于83/124例(66.9%)患者。

关键数值与推荐

  • 24周ORR:总体38.0%(95%CI 28.8%–47.8%);MSI-high 63.6%(95%CI 30.8%–89.1%);MSS 36.2%(95%CI 26.5%–46.7%)。
  • 中位DOR:21.2个月(95%CI 7.6个月–不可估计)。
  • 中位PFS:7.4个月(95%CI 5.3–8.7个月)。
  • 中位OS:16.7个月(95%CI 15.0个月–不可估计)。
  • 3级或4级治疗相关不良事件:83/124例(66.9%)。

临床怎么用

  • 对于既往系统治疗后进展的晚期子宫内膜癌患者,可考虑仑伐替尼联合帕博利珠单抗方案。
  • 疗效观察不受肿瘤MSI状态限制,MSI-high与MSS患者均可能获益。
  • 治疗期间需关注3级或4级治疗相关不良事件,该研究中发生率为66.9%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with advanced endometrial carcinoma have limited treatment options. We report final primary efficacy analysis results for a patient cohort with advanced endometrial carcinoma receiving lenvatinib plus pembrolizumab in an ongoing phase Ib/II study of selected solid tumors. METHODS: Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles. The primary end point was objective response rate (ORR) at 24 weeks (ORRWk24); secondary efficacy end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Tumor assessments were evaluated by investigators per immune-related RECIST. RESULTS: At data cutoff, 108 patients with previously treated endometrial carcinoma were enrolled, with a median follow-up of 18.7 months. The ORRWk24 was 38.0% (95% CI, 28.8% to 47.8%). Among subgroups, the ORRWk24 (95% CI) was 63.6% (30.8% to 89.1%) in patients with microsatellite instability (MSI)-high tumors (n = 11) and 36.2% (26.5% to 46.7%) in patients with microsatellite-stable tumors (n = 94). For previously treated patients, regardless of tumor MSI status, the median DOR was 21.2 months (95% CI, 7.6 months to not estimable), median PFS was 7.4 months (95% CI, 5.3 to 8.7 months), and median OS was 16.7 months (15.0 months to not estimable). Grade 3 or 4 treatment-related adverse events occurred in 83/124 (66.9%) patients. CONCLUSION: Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020. PMID: 32167863. doi:10.1200/JCO.19.02627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。